RDU Webinar Series: A Discussion on KRAS Testing and Treatment

Recorded On: 05/04/2016

Capturing KRAS Testing for Stage IV Colorectal Cancer Cases: A Tale of Two States: The objective of this presentation is to provide background information on the KRAS Site-Specific Factor, explain the quality control approach and data sources used to re-review cases, describe findings related to the frequency, data sources and timing of missed KRAS testing, and present models that illustrate patient and facility characteristics associated with KRAS testing. In addition, we plan to discuss the potential implications of our findings.

KRAS Testing and Treatment among Patients with Metastatic Colorectal Cancer: We will discuss findings on KRAS testing and treatment patterns from the Comparative Effectiveness Research project conducted with 10 registries in CDC's National Program of Cancer Registries. The objectives are to understand KRAS biomarker testing among patients with metastatic colorectal cancer and to explore the association of having a documented KRAS test and KRAS results to first line treatment, particularly EGRF inhibitor treatment. We will also compare our results with similar, earlier studies using data from SEER and eight Cancer Research Network sites.


Mary Anne Lynch, MPH
Early Case Capture (PYAC) Study Coordinator
Louisiana Tumor Registry

Mary E Charlton, PhD
Assistant Professor in the Department of Epidemiology
Co-Investigator of the Iowa Cancer Registry

Lori A. (Loria) Pollack, MD, MPH
CAPT, U.S. Public Health Service| Medical Epidemiologist,
Centers for Disease Control and Prevention (CDC)